Thoughts on Allogene CAR-T Pipeline Update; Q1 2020 Call Summary
On Wednesday, May 6, Allogene held their Q1 2020 earnings call (press release / slides), highlighting the off-the-shelf benefits allogeneic products have over autologous products, particularly during the COVID-19 pandemic. Below, Celltelligence provides thoughts on Allogene’s cell therapy program in the context of the ongoing health emergency.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.